Supplementary Table S3: STROBE statement

	Item	Recommendation	Comment
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	(a) Indicated in "Abstract"
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	(b) Provided in "Abstract"
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Explained in "Introduction" paragraphs 1 and 2
Objectives	3	State specific objectives, including any prespecified hypotheses	Stated in "Introduction" paragraph 3
Methods			
Study design	4	Present key elements of study design early in the paper	Presented in "Methods", subsection "Study design" and "Participants"
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Described in "Methods", subsection "Study design", "Participants" and "Diagnostic material and tests"
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Given in "Methods", subsection "Study design" and "Participants"
		(*b*) For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give	Given in "Methods", subsection "Study design", "Participants" and "Diagnostic material and tests"

		diagnostic criteria, if applicable	
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Given in “Methods”, subsection “Diagnostic material and tests”
Bias	9	Describe any efforts to address potential sources of bias	Described in “Methods”, subsection “Study design” and “Participants”
Study size	10	Explain how the study size was arrived at	Explained in “Methods”, subsection “Study design” and “Participants”
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Explained in “Methods”, subsection “Statistical analysis”
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Described in “Methods”, subsection “Statistical analysis”
		(*b*) Describe any methods used to examine subgroups and interactions	Described in “Methods”, subsection “Statistical analysis”
		(*c*) Explain how missing data were addressed	NA
		(*d*) If applicable, explain how matching of cases and controls was addressed	NA
		(*e*) Describe any sensitivity analyses	NA
Results			
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study,	Reported in “Results”, subsection “CAPA classification and ICU mortality”

		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Given in “Table 1”
		(b) Indicate number of participants with missing data for each variable of interest	Indicated in “Supplementary Table S1”
Outcome data	15	Report numbers in each exposure category, or summary measures of exposure	Reported in “Tables 2” and “Table 3”
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Given in “Results”, “Table 1” and “Table 3”
		(*b*) Report category boundaries when continuous variables were categorized	NA
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Reported in “Results”, subsection “BAL GM and ICU mortality”, “Serum fungal markers and ICU mortality” and “Antifungal treatment and ICU mortality”

Discussion

Key results	18	Summarise key results with reference to study objectives	Summarised in “Discussion” paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussed in “Discussion” paragraph 2 and 3
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Given in “Discussion” paragraph 4
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Given in “Funding” and “Potential conflict of interest”